Pictet Asset Management Holding SA Has $125.78 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Pictet Asset Management cut its stake in Alnylam by 18.4% in Q4, selling 71,493 shares and ending the quarter with 316,053 shares valued at $125,782,000 (about 0.24% of the company).
• Insiders sold 38,656 shares worth $12,370,696 in the last quarter (including EVP Kevin Fitzgerald and EVP Jeffrey Poulton), leaving insiders with 0.86% ownership while institutions/hedge funds own roughly 92.97%.
• Analysts collectively rate Alnylam a “Moderate Buy” with a consensus target of $472.78 despite several price-target cuts, and the company recently missed quarterly EPS ($1.25 vs. $1.43) and revenue ($1.10B vs. $1.16B) even as revenue rose 84.9% year-over-year.

Pictet Asset Management Holding SA cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 18.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 316,053 shares of the biopharmaceutical company's stock after selling 71,493 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.24% of Alnylam Pharmaceuticals worth $125,782,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Howard Capital Management Inc. increased its stake in shares of Alnylam Pharmaceuticals by 2.9% in the third quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company's stock worth $389,000 after acquiring an additional 24 shares during the last quarter. Frank Rimerman Advisors LLC increased its stake in shares of Alnylam Pharmaceuticals by 2.0% in the third quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company's stock worth $570,000 after acquiring an additional 24 shares during the last quarter. Coastal Bridge Advisors LLC increased its stake in shares of Alnylam Pharmaceuticals by 2.3% in the third quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company's stock worth $500,000 after acquiring an additional 25 shares during the last quarter. Meridian Financial Advisors LLC increased its stake in shares of Alnylam Pharmaceuticals by 3.5% in the third quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company's stock worth $378,000 after acquiring an additional 28 shares during the last quarter. Finally, First Horizon Corp increased its stake in shares of Alnylam Pharmaceuticals by 20.7% in the fourth quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company's stock worth $65,000 after acquiring an additional 28 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ALNY shares. Truist Financial dropped their price target on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a "buy" rating on the stock in a research note on Monday, April 13th. Needham & Company LLC dropped their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a "buy" rating on the stock in a research note on Thursday, February 12th. Bank of America reaffirmed a "buy" rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Morgan Stanley lowered their target price on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an "equal weight" rating on the stock in a research report on Friday, January 30th. Finally, HC Wainwright reissued a "buy" rating and set a $510.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $472.78.

Insider Buying and Selling

In other news, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the firm's stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $319.73, for a total value of $528,193.96. Following the sale, the executive vice president directly owned 21,860 shares of the company's stock, valued at approximately $6,989,297.80. This trade represents a 7.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,206 shares of the firm's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $722,795.90. Following the completion of the sale, the executive vice president directly owned 64,273 shares in the company, valued at approximately $21,059,048.45. This represents a 3.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 38,656 shares of company stock valued at $12,370,696 in the last quarter. Insiders own 0.86% of the company's stock.

Alnylam Pharmaceuticals Trading Up 1.0%

Alnylam Pharmaceuticals stock opened at $308.51 on Tuesday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The company has a market capitalization of $41.16 billion, a price-to-earnings ratio of 180.42 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a one year low of $245.96 and a one year high of $495.55. The company's fifty day moving average price is $321.95 and its two-hundred day moving average price is $379.57.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). The business had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company's quarterly revenue was up 84.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.65) earnings per share. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.75 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.